Sarcopenia and serum biomarkers of oxidative stress after a 6-month physical activity intervention in women with metastatic breast cancer: results from the ABLE feasibility trial.
Metastatic breast cancer
Oxidative stress
Physical activity
Sarcopenia
Skeletal muscle index
Toxicity
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
04
02
2021
accepted:
20
04
2021
pubmed:
21
5
2021
medline:
14
7
2021
entrez:
20
5
2021
Statut:
ppublish
Résumé
Sarcopenia has been identified as an important prognostic factor for patients with cancer. This study aimed at exploring the potential associations between a 6-month physical activity intervention and muscle characteristics, sarcopenia, oxidative stress and toxicities in patients with metastatic breast cancer. Women newly diagnosed with metastatic breast cancer (N = 49) participated in an unsupervised, personalized, 6-month physical activity intervention with activity tracker. Computerized tomography images at the third lumbar vertebra were analysed at baseline, three months and six months to assess sarcopenia (muscle mass index < 40 cm At baseline 53% (mean age 55 years (SD 10.41)) were sarcopenic and 75% had poor muscle quality. Muscle cross sectional area, skeletal muscle radiodensity, lean body mass remained constant over the six months (p = 0.75, p = 0.07 and p = 0.75 respectively), but differed significantly between sarcopenic and non-sarcopenic patients at baseline and 6-months. Sarcopenic patients at baseline were more likely to have an increase of MDA (p = 0.02) at 6 months. Being sarcopenic during at least one moment during the 6-month study was associated with a higher risk of developing severe toxicities (grade > 2) (p = 0.02). This study suggests potential benefits of physical activity for maintenance of muscle mass. Sarcopenia can alter many parameters and disturb the pro and antioxidant balance.
Identifiants
pubmed: 34013451
doi: 10.1007/s10549-021-06238-z
pii: 10.1007/s10549-021-06238-z
pmc: PMC8272711
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
601-613Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021. The Author(s).
Références
Cardoso F, Costa A, Senkus E et al (2017) 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol 28:16–33. https://doi.org/10.1093/annonc/mdw544
doi: 10.1093/annonc/mdw544
pubmed: 28177437
O’Shaughnessy J (2005) Extending survival with chemotherapy in metastatic breast cancer. Oncologist 10(Suppl 3):20–29. https://doi.org/10.1634/theoncologist.10-90003-20
doi: 10.1634/theoncologist.10-90003-20
pubmed: 16368868
Diaby V, Tawk R, Sanogo V et al (2015) A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer. Breast Cancer Res Treat 151:27–40. https://doi.org/10.1007/s10549-015-3383-6
doi: 10.1007/s10549-015-3383-6
pubmed: 25893588
pmcid: 4530780
Cruz-Jentoft AJ, Baeyens JP, Bauer JM et al (2010) Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing 39:412–423. https://doi.org/10.1093/ageing/afq034
doi: 10.1093/ageing/afq034
pubmed: 20392703
pmcid: 2886201
Kiss N, Loeliger J, Findlay M et al (2020) Clinical Oncology Society of Australia: position statement on CANCER-RELATED malnutrition and sarcopenia. Nutr Diet 77:416–425. https://doi.org/10.1111/1747-0080.12631
doi: 10.1111/1747-0080.12631
pubmed: 32803904
pmcid: 7540290
Cruz-Jentoft AJ, Bahat G, Bauer J et al (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48:601. https://doi.org/10.1093/ageing/afz046
doi: 10.1093/ageing/afz046
pubmed: 31081853
pmcid: 6593317
Shachar SS, Williams GR, Muss HB, Nishijima TF (2016) Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review. Eur J Cancer 57:58–67. https://doi.org/10.1016/j.ejca.2015.12.030
doi: 10.1016/j.ejca.2015.12.030
pubmed: 26882087
Zhang X-M, Dou Q-L, Zeng Y et al (2020) Sarcopenia as a predictor of mortality in women with breast cancer: a meta-analysis and systematic review. BMC Cancer 20:172. https://doi.org/10.1186/s12885-020-6645-6
doi: 10.1186/s12885-020-6645-6
pubmed: 32131764
pmcid: 7057618
Rier HN, Jager A, Sleijfer S et al (2017) Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy. Breast 31:9–15. https://doi.org/10.1016/j.breast.2016.10.014
doi: 10.1016/j.breast.2016.10.014
pubmed: 27810702
pmcid: 27810702
Shachar SS, Deal AM, Weinberg M et al (2017) Skeletal muscle measures as predictors of toxicity, hospitalization, and survival in patients with metastatic breast cancer receiving taxane-based chemotherapy. Clin Cancer Res 23:658–665. https://doi.org/10.1158/1078-0432.CCR-16-0940
doi: 10.1158/1078-0432.CCR-16-0940
pubmed: 27489287
Versteeg KS, Blauwhoff-Buskermolen S, Buffart LM et al (2018) Higher muscle strength is associated with prolonged survival in older patients with advanced cancer. Oncologist 23:580–585. https://doi.org/10.1634/theoncologist.2017-0193
doi: 10.1634/theoncologist.2017-0193
pubmed: 29222198
Prado CMM, Baracos VE, McCargar LJ et al (2009) Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 15:2920–2926. https://doi.org/10.1158/1078-0432.CCR-08-2242
doi: 10.1158/1078-0432.CCR-08-2242
pubmed: 19351764
Franzoi MA, Vandeputte C, Eiger D et al (2020) Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors. Breast Cancer Res Treat 181:199–209. https://doi.org/10.1007/s10549-020-05617-2
doi: 10.1007/s10549-020-05617-2
pubmed: 32246377
Aubrey J, Esfandiari N, Baracos VE et al (2014) Measurement of skeletal muscle radiation attenuation and basis of its biological variation. Acta Physiol (Oxf) 210:489–497. https://doi.org/10.1111/apha.12224
doi: 10.1111/apha.12224
Goodpaster BH, Chomentowski P, Ward BK et al (2008) Effects of physical activity on strength and skeletal muscle fat infiltration in older adults: a randomized controlled trial. J Appl Physiol 105:1498–1503. https://doi.org/10.1152/japplphysiol.90425.2008
doi: 10.1152/japplphysiol.90425.2008
pubmed: 18818386
pmcid: 2584841
Prado CMM, Baracos VE, McCargar LJ et al (2007) Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 13:3264–3268. https://doi.org/10.1158/1078-0432.CCR-06-3067
doi: 10.1158/1078-0432.CCR-06-3067
pubmed: 17545532
Prado CMM, Lima ISF, Baracos VE et al (2011) An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. Cancer Chemother Pharmacol 67:93–101. https://doi.org/10.1007/s00280-010-1288-y
doi: 10.1007/s00280-010-1288-y
pubmed: 20204364
Iwase T, Sangai T, Nagashima T et al (2016) Impact of body fat distribution on neoadjuvant chemotherapy outcomes in advanced breast cancer patients. Cancer Med 5:41–48. https://doi.org/10.1002/cam4.571
doi: 10.1002/cam4.571
pubmed: 26626021
Barret M, Antoun S, Dalban C et al (2014) Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer. Nutr Cancer 66:583–589. https://doi.org/10.1080/01635581.2014.894103
doi: 10.1080/01635581.2014.894103
pubmed: 24707897
Antoun S, Baracos VE, Birdsell L et al (2010) Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol 21:1594–1598. https://doi.org/10.1093/annonc/mdp605
doi: 10.1093/annonc/mdp605
pubmed: 20089558
Massicotte M-H, Borget I, Broutin S et al (2013) Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study. J Clin Endocrinol Metab 98:2401–2408. https://doi.org/10.1210/jc.2013-1115
doi: 10.1210/jc.2013-1115
pubmed: 23543666
Aleixo GFP, Williams GR, Nyrop KA et al (2019) Muscle composition and outcomes in patients with breast cancer: meta-analysis and systematic review. Breast Cancer Res Treat 177:569–579. https://doi.org/10.1007/s10549-019-05352-3
doi: 10.1007/s10549-019-05352-3
pubmed: 31292800
Villaseñor A, Ballard-Barbash R, Baumgartner K et al (2012) Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL Study. J Cancer Surviv 6:398–406. https://doi.org/10.1007/s11764-012-0234-x
doi: 10.1007/s11764-012-0234-x
pubmed: 23054848
pmcid: 3747827
Del Fabbro E, Parsons H, Warneke CL et al (2012) The relationship between body composition and response to neoadjuvant chemotherapy in women with operable breast cancer. Oncologist 17:1240–1245. https://doi.org/10.1634/theoncologist.2012-0169
doi: 10.1634/theoncologist.2012-0169
pubmed: 22903527
pmcid: 3481889
Wong AL, Seng KY, Ong EM et al (2014) Body fat composition impacts the hematologic toxicities and pharmacokinetics of doxorubicin in Asian breast cancer patients. Breast Cancer Res Treat 144:143–152. https://doi.org/10.1007/s10549-014-2843-8
doi: 10.1007/s10549-014-2843-8
pubmed: 24481679
Shachar SS, Deal AM, Weinberg M et al (2017) Body composition as a predictor of toxicity in patients receiving anthracycline and taxane-based chemotherapy for early-stage breast cancer. Clin Cancer Res 23:3537–3543. https://doi.org/10.1158/1078-0432.CCR-16-2266
doi: 10.1158/1078-0432.CCR-16-2266
pubmed: 28143874
pmcid: 5511549
Huillard O, Mir O, Peyromaure M et al (2013) Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br J Cancer 108:1034–1041. https://doi.org/10.1038/bjc.2013.58
doi: 10.1038/bjc.2013.58
pubmed: 23462722
pmcid: 3619075
Mir O, Coriat R, Blanchet B et al (2012) Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS ONE 7:e37563. https://doi.org/10.1371/journal.pone.0037563
doi: 10.1371/journal.pone.0037563
pubmed: 22666367
pmcid: 3364283
Du Bois D, Du Bois EF (1989) A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition 5:303–311 (discussion 312-313)
pubmed: 2520314
Prado CMM, Lieffers JR, McCargar LJ et al (2008) Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 9:629–635. https://doi.org/10.1016/S1470-2045(08)70153-0
doi: 10.1016/S1470-2045(08)70153-0
pubmed: 18539529
Antoun S, Borget I, Lanoy E (2013) Impact of sarcopenia on the prognosis and treatment toxicities in patients diagnosed with cancer. Curr Opin Support Palliat Care 7:383–389. https://doi.org/10.1097/SPC.0000000000000011
doi: 10.1097/SPC.0000000000000011
pubmed: 24189893
Jung H-W, Kim JW, Kim J-Y et al (2015) Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy. Support Care Cancer 23:687–694. https://doi.org/10.1007/s00520-014-2418-6
doi: 10.1007/s00520-014-2418-6
pubmed: 25163434
Courneya KS, Segal RJ, Mackey JR et al (2007) Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. J Clin Oncol 25:4396–4404. https://doi.org/10.1200/JCO.2006.08.2024
doi: 10.1200/JCO.2006.08.2024
pubmed: 17785708
Speck RM, Courneya KS, Mâsse LC et al (2010) An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. J Cancer Surviv 4:87–100. https://doi.org/10.1007/s11764-009-0110-5
doi: 10.1007/s11764-009-0110-5
Adams SC, Segal RJ, McKenzie DC et al (2016) Impact of resistance and aerobic exercise on sarcopenia and dynapenia in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. Breast Cancer Res Treat 158:497–507. https://doi.org/10.1007/s10549-016-3900-2
doi: 10.1007/s10549-016-3900-2
pubmed: 27394134
Shen W, Punyanitya M, Wang Z et al (2004) Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol 97:2333–2338. https://doi.org/10.1152/japplphysiol.00744.2004
doi: 10.1152/japplphysiol.00744.2004
pubmed: 15310748
Can B, Kara O, Kizilarslanoglu MC et al (2017) Serum markers of inflammation and oxidative stress in sarcopenia. Aging Clin Exp Res 29:745–752. https://doi.org/10.1007/s40520-016-0626-2
doi: 10.1007/s40520-016-0626-2
pubmed: 27571781
Coto Montes A, Boga JA, Bermejo Millo C et al (2017) Potential early biomarkers of sarcopenia among independent older adults. Maturitas 104:117–122. https://doi.org/10.1016/j.maturitas.2017.08.009
doi: 10.1016/j.maturitas.2017.08.009
pubmed: 28923171
Puig-Vilanova E, Rodriguez DA, Lloreta J et al (2015) Oxidative stress, redox signaling pathways, and autophagy in cachectic muscles of male patients with advanced COPD and lung cancer. Free Radical Biol Med 79:91–108. https://doi.org/10.1016/j.freeradbiomed.2014.11.006
doi: 10.1016/j.freeradbiomed.2014.11.006
Sullivan-Gunn MJ, Lewandowski PA (2013) Elevated hydrogen peroxide and decreased catalase and glutathione peroxidase protection are associated with aging sarcopenia. BMC Geriatr 13:104. https://doi.org/10.1186/1471-2318-13-104
doi: 10.1186/1471-2318-13-104
pubmed: 24093947
pmcid: 3853025
Delrieu L, Pérol O, Fervers B et al (2018) A Personalized physical activity program with activity trackers and a mobile phone app for patients with metastatic breast cancer: protocol for a single-arm feasibility trial. JMIR Res Protocols 7:e10487. https://doi.org/10.2196/10487
doi: 10.2196/10487
Tudor-Locke C, Hatano Y, Pangrazi RP, Kang M (2008) Revisiting “how many steps are enough?” Med Sci Sports Exerc 40:S537-543. https://doi.org/10.1249/MSS.0b013e31817c7133
doi: 10.1249/MSS.0b013e31817c7133
pubmed: 18562971
Hjermstad MJ, Fossa SD, Bjordal K, Kaasa S (1995) Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire. J Clin Oncol 13:1249–1254
doi: 10.1200/JCO.1995.13.5.1249
Galiano-Castillo N, Arroyo-Morales M, Ariza-Garcia A et al (2016) The six-minute walk test as a measure of health in breast cancer patients. J Aging Phys Act 24:508–515. https://doi.org/10.1123/japa.2015-0056
doi: 10.1123/japa.2015-0056
pubmed: 26796231
Savva C, Karagiannis C, Rushton A (2013) Test–retest reliability of grip strength measurement in full elbow extension to evaluate maximum grip strength. J Hand Surg Eur 38:183–186. https://doi.org/10.1177/1753193412449804
doi: 10.1177/1753193412449804
Crinière L, Lhommet C, Caille A et al (2011) Reproducibility and validity of the French version of the long international physical activity questionnaire in patients with type 2 diabetes. J Phys Act Health 8:858–865
doi: 10.1123/jpah.8.6.858
Gomez-Perez SL, Haus JM, Sheean P et al (2016) Measuring abdominal circumference and skeletal muscle from a single cross-sectional computed tomography image: a step-by-step guide for clinicians using National Institutes of Health ImageJ. J Parenter Enter Nutr 40:308–318. https://doi.org/10.1177/0148607115604149
doi: 10.1177/0148607115604149
Schneider CA, Rasband WS, Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9:671–675
doi: 10.1038/nmeth.2089
McLean RR, Kiel DP (2015) Developing consensus criteria for sarcopenia: an update. J Bone Miner Res 30:588–592. https://doi.org/10.1002/jbmr.2492
doi: 10.1002/jbmr.2492
pubmed: 25735999
Mitsiopoulos N, Baumgartner RN, Heymsfield SB et al (1998) Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol 85:115–122
doi: 10.1152/jappl.1998.85.1.115
Mourtzakis M, Prado CMM, Lieffers JR et al (2008) A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 33:997–1006. https://doi.org/10.1139/H08-075
doi: 10.1139/H08-075
pubmed: 18923576
Caan BJ, Cespedes Feliciano EM, Prado CM et al (2018) Association of muscle and adiposity measured by computed tomography with survival in patients with nonmetastatic breast cancer. JAMA Oncol 4:798. https://doi.org/10.1001/jamaoncol.2018.0137
doi: 10.1001/jamaoncol.2018.0137
pubmed: 29621380
pmcid: 6584322
Faiss R, Pialoux V, Sartori C et al (2013) Ventilation, oxidative stress, and nitric oxide in hypobaric versus normobaric hypoxia. Med Sci Sports Exerc 45:253–260. https://doi.org/10.1249/MSS.0b013e31826d5aa2
doi: 10.1249/MSS.0b013e31826d5aa2
pubmed: 22895381
Ribon-Demars A, Pialoux V, Boreau A et al (2018) Protective roles of estradiol against vascular oxidative stress in ovariectomized female rats exposed to normoxia or intermittent hypoxia. Acta Physiol (Oxf). https://doi.org/10.1111/apha.13159
Delrieu L, Pialoux V, Pérol O et al (2020) Feasibility and Health benefits of an individualized physical activity intervention in women with metastatic breast cancer: intervention Study. JMIR Mhealth Uhealth 8:e12306. https://doi.org/10.2196/12306
doi: 10.2196/12306
pubmed: 32012082
pmcid: 7013652
Jeejeebhoy KN (2012) Malnutrition, fatigue, frailty, vulnerability, sarcopenia and cachexia: overlap of clinical features. Curr Opin Clin Nutr Metab Care 15:213–219. https://doi.org/10.1097/MCO.0b013e328352694f
doi: 10.1097/MCO.0b013e328352694f
pubmed: 22450775
Kim TN, Choi KM (2013) Sarcopenia: definition, epidemiology, and pathophysiology. J Bone Metab 20:1–10. https://doi.org/10.11005/jbm.2013.20.1.1
doi: 10.11005/jbm.2013.20.1.1
pubmed: 24524049
pmcid: 3780834
Rolland Y, Czerwinski S, Abellan Van Kan G et al (2008) Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives. J Nutr Health Aging 12:433–450
doi: 10.1007/BF02982704
Tsai S (2012) Importance of lean body mass in the oncologic patient. Nutr Clin Pract 27:593–598. https://doi.org/10.1177/0884533612457949
doi: 10.1177/0884533612457949
pubmed: 22898746
Kazemi-Bajestani SMR, Becher H, Fassbender K et al (2014) Concurrent evolution of cancer cachexia and heart failure: bilateral effects exist. J Cachexia Sarcopenia Muscle 5:95–104. https://doi.org/10.1007/s13539-014-0137-y
doi: 10.1007/s13539-014-0137-y
pubmed: 24627226
pmcid: 4053562
Brioche T, Lemoine-Morel S (2016) Oxidative stress, sarcopenia, antioxidant strategies and exercise: molecular aspects. Curr Pharm Des 22:2664–2678
doi: 10.2174/1381612822666160219120531
Prado CMM, Lieffers JR, Bowthorpe L et al (2013) Sarcopenia and physical function in overweight patients with advanced cancer. Can J Diet Pract Res 74:69–74. https://doi.org/10.3148/74.2.2013.69
doi: 10.3148/74.2.2013.69
pubmed: 23750978
Rier HN, Jager A, Sleijfer S et al (2016) The prevalence and prognostic value of low muscle mass in cancer patients: a review of the literature. Oncologist. https://doi.org/10.1634/theoncologist.2016-0066
doi: 10.1634/theoncologist.2016-0066
pubmed: 27412391
pmcid: 5189631
Sheean P, Gomez-Perez S, Joyce C et al (2019) Body composition, serum biomarkers of inflammation and quality of life in clinically stable women with estrogen receptor positive metastatic breast cancer. Nutr Cancer 71:981–991. https://doi.org/10.1080/01635581.2019.1595053
doi: 10.1080/01635581.2019.1595053
pubmed: 31037968
Martin L, Birdsell L, MacDonald N et al (2013) Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of Body Mass Index. JCO 31:1539–1547. https://doi.org/10.1200/JCO.2012.45.2722
doi: 10.1200/JCO.2012.45.2722
Fearon K, Strasser F, Anker SD et al (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12:489–495. https://doi.org/10.1016/S1470-2045(10)70218-7
doi: 10.1016/S1470-2045(10)70218-7
pubmed: 21296615
Martin L, Birdsell L, Macdonald N et al (2013) Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 31:1539–1547. https://doi.org/10.1200/JCO.2012.45.2722
doi: 10.1200/JCO.2012.45.2722
pubmed: 23530101
Sandini M, Bernasconi DP, Fior D et al (2016) A high visceral adipose tissue-to-skeletal muscle ratio as a determinant of major complications after pancreatoduodenectomy for cancer. Nutrition 32:1231–1237. https://doi.org/10.1016/j.nut.2016.04.002
doi: 10.1016/j.nut.2016.04.002
pubmed: 27261062
Bohannon RW, Crouch R (2017) Minimal clinically important difference for change in 6-minute walk test distance of adults with pathology: a systematic review: Systematic review of MCID in 6MWT. J Eval Clin Pract 23:377–381. https://doi.org/10.1111/jep.12629
doi: 10.1111/jep.12629
pubmed: 27592691
Schmidt K, Vogt L, Thiel C et al (2013) Validity of the six-minute walk test in cancer patients. Int J Sports Med 34:631–636. https://doi.org/10.1055/s-0032-1323746
doi: 10.1055/s-0032-1323746
pubmed: 23444095
Solway S, Brooks D, Lacasse Y, Thomas S (2001) A qualitative systematic overview of the measurement properties of functional walk tests used in the cardiorespiratory domain. Chest 119:256–270
doi: 10.1378/chest.119.1.256
Mazzuca F, Onesti CE, Roberto M et al (2018) Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines. Oncotarget 9:25714–25722. https://doi.org/10.18632/oncotarget.25394
doi: 10.18632/oncotarget.25394
pubmed: 29876019
pmcid: 5986630
Solomayer E-F, Braun E-M, Zimmermann JSM et al (2019) Muscle mass loss in patients with metastatic breast cancer. Arch Gynecol Obstet 300:201–206. https://doi.org/10.1007/s00404-019-05168-y
doi: 10.1007/s00404-019-05168-y
pubmed: 31044301
Rier HN, Jager A, Sleijfer S et al (2018) Changes in body composition and muscle attenuation during taxane-based chemotherapy in patients with metastatic breast cancer. Breast Cancer Res Treat 168:95–105. https://doi.org/10.1007/s10549-017-4574-0
doi: 10.1007/s10549-017-4574-0
pubmed: 29147870
Ábrigo J, Elorza AA, Riedel CA et al (2018) Role of oxidative stress as key regulator of muscle wasting during cachexia. Oxid Med Cell Longev 2018:1–17. https://doi.org/10.1155/2018/2063179
doi: 10.1155/2018/2063179
Peixoto da Silva S, Santos JMO, Costa e Silva MP et al (2020) Cancer cachexia and its pathophysiology: links with sarcopenia, anorexia and asthenia. J Cachexia Sarcopenia Muscle 11:619–635. https://doi.org/10.1002/jcsm.12528
doi: 10.1002/jcsm.12528
pubmed: 32142217
pmcid: 7296264
Bellanti F, Romano AD, Lo Buglio A et al (2018) Oxidative stress is increased in sarcopenia and associated with cardiovascular disease risk in sarcopenic obesity. Maturitas 109:6–12. https://doi.org/10.1016/j.maturitas.2017.12.002
doi: 10.1016/j.maturitas.2017.12.002
pubmed: 29452783
pmcid: 29452783
Kundaktepe BP, Sozer V, Durmus S et al (2021) The evaluation of oxidative stress parameters in breast and colon cancer. Medicine (Baltimore) 100:e25104. https://doi.org/10.1097/MD.0000000000025104
doi: 10.1097/MD.0000000000025104
Jelic MD, Mandic AD, Maricic SM, Srdjenovic BU (2021) Oxidative stress and its role in cancer. J Cancer Res Ther 17:22–28. https://doi.org/10.4103/jcrt.JCRT_862_16
doi: 10.4103/jcrt.JCRT_862_16
pubmed: 33723127
Zińczuk J, Maciejczyk M, Zaręba K, et al (2019) Antioxidant Barrier, Redox Status, and Oxidative Damage to Biomolecules in Patients with Colorectal Cancer. Can Malondialdehyde and Catalase Be Markers of Colorectal Cancer Advancement? Biomolecules. https://doi.org/10.3390/biom9100637
Shrivastava A, Mishra SP, Pradhan S et al (2021) An assessment of serum oxidative stress and antioxidant parameters in patients undergoing treatment for cervical cancer. Free Radic Biol Med 167:29–35. https://doi.org/10.1016/j.freeradbiomed.2021.02.037
doi: 10.1016/j.freeradbiomed.2021.02.037
pubmed: 33705962
Li F, Liu W, Huo F et al (2021) Effect of self-controlled exercise on antioxidant activity of red blood cells and functional recovery of limbs in patients with breast cancer after rehabilitation. Iran J Public Health 50:306–314. https://doi.org/10.18502/ijph.v50i2.5345
doi: 10.18502/ijph.v50i2.5345
pubmed: 33747994
pmcid: 7956092
Cousin S, Hollebecque A, Koscielny S et al (2014) Low skeletal muscle is associated with toxicity in patients included in phase I trials. Investig New Drugs 32:382–387. https://doi.org/10.1007/s10637-013-0053-6
doi: 10.1007/s10637-013-0053-6
Cespedes Feliciano EM, Popuri K, Cobzas D et al (2020) Evaluation of automated computed tomography segmentation to assess body composition and mortality associations in cancer patients. J Cachexia Sarcopenia Muscle. https://doi.org/10.1002/jcsm.12573
doi: 10.1002/jcsm.12573
pubmed: 32314543
pmcid: 7567141
Prado CM, Purcell SA, Laviano A (2020) Nutrition interventions to treat low muscle mass in cancer. J Cachexia Sarcopenia Muscle 11:366–380. https://doi.org/10.1002/jcsm.12525
doi: 10.1002/jcsm.12525
pubmed: 31916411
pmcid: 7113510